Bridging the gap between innovation and capital
5AM Ventures
Focus on Biotech Therapeutic Companies
Program
5AM Ventures invests globally in private and public biopharmaceutical companies advancing innovative therapies. The firm has raised over $2.2 billion across venture funds focused on company creation and growth-stage private investments, as well as a public long-only fund targeting small- and mid-cap biopharma companies.
Event
LaunchBio, Browne Consulting, and Silicon Valley Bank, a division of First Citizens Bank, with support by Fondation Ipsen, are pleased to announce their next Investor Connect virtual event with 5AM Ventures.
Since its founding in 2002, more than 40 portfolio companies, many created or seeded by 5AM have completed IPOs and M&A transactions. The team of over 25 professionals, based primarily in Boston and San Francisco, brings deep scientific and operational expertise across the biopharmaceutical sector. 5AM Ventures is very modality and therapeutic area agnostic and is open to the right tools/diagnostics in addition to therapeutics as well. The firm is also interested in rare genetic diseases.
Applications will be selected based on meeting the following criteria:
Geography
Open to Investments in North America
Company type
Early to late stage pre-clinical therapeutics with a relatively clear line of sight to the clinic.
Modalities of Interest
(Agnostic, but some that are of special interest)
- Protein-based therapies
- Small molecule
- Oligotherapies (RNA, ASOs, etc.)
- Biologics
- Regenerative Medicine
- CRISPR-based therapies
- Microbiome-based therapies
Stage
Companies seeking funding for Pre-Seed, Seed, Series A and Series B.
Qualifying start-ups can apply here today.
Applications are accepted on a rolling basis. Learn more about LaunchBio’s Investor Connect series, in partnership with Browne Consulting and Silicon Valley Bank, a division of First Citizens Bank.